MULTIDISCIPLINARY APPROACH to Oesophageal and gastric cancer



    This book aims at highlighting the present and very dynamic development in the field of pper GI cancers. Oesophageal and gastric cancer are diseases with poor prognosis. Looking back to ous efforts to treat these serious malignancies have been dated already to the ancient periods. The introductory chapter of this issue is therefore dedicated to history of gastric cancer that is tightly connected to history of development of surgical techniques. Surgery remains the basic cornerstone of the treatment of localized oesophageal and gastric cancer and chapters attributed to surgery delineate the sustained development either in classical surgical techniques but also an implementation of new technologies, especially robotic surgery into clinical practice.

    Price: 790 CZK (31EUR),  Pre-order: info@currentmedia.cz




Actual articles

News in pain treatment

02/2020 MUDr. Štěpán Rusín
Good and adequate analgesia is a fundamental right of every patient. Although quality pain management is much more affordable today, the quality of pain management is still dependent on the active interest of healthcare professionals and the organization of acute and chronic pain management in the workplace. The high-quality analgesia has been repeatedly proven to be associated with a reduction in morbidity, faster recovery and discharge from the hospital.

Strategies sequential treatment of metastatic castration‑resistant prostate cancer

02/2020 MUDr. Igor Richter, Ph.D.; doc. MUDr. Josef Dvořák, Ph.D.; MUDr. Vladimír Šámal, Ph.D.; MUDr. Jiří Bartoš, MBA
Prostate cancer is the most common male malignant neoplasm in men worldwide and second cause of cancer related death. During the last decade, the treatment of metastatic castration resistant prostate cancer has dramatically changed with the approval of new agents as cabazitaxel, enzalutamide, abiraterone and radium 223. These new therapeutic options have provided an overall survival increase from 14-18 months to average of 30-36 months. The problem is the absence of the clearly defined predictive marker. In this review we discussing to choose the optimal treatment sequence of this disease.

Clinical dilemma of lung cancer treatment with anti‑PD‑1 therapy (nivolumab) in the discovery of rheumatological problems with joint swelling

02/2020 MUDr. Markéta Černovská
Immunotherapy is the use of medicines to stimulate a person's own immune system to recognize and destroy cancer cells more effectively. Nivolumab can be used in people with certain types of advanced NSCLC whose cancer starts growing again after chemotherapy. But immunotherapy drugs can cause side effects, including rare complications that, for some patients, may be life threatening, but most side effects are mild to moderate in severity and respond to treatments such as steroids. It’s very important to report any new side as soon as possible. Although rheumatic immune-related adverse events are rarely life-threatening, patients' quality of life can be considerably restricted due to pain, stiffness and limited mobility.